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The fatal neurodegenerative disorders amyotrophic lat-
eral sclerosis and spinal muscular atrophy are, respec-
tively, the most common motoneuron disease and genetic
cause of infant death. Various in vitromodel systems have
been established to investigate motoneuron disease
mechanisms, in particular immortalized cell lines and pri-
mary neurons. Using quantitative mass-spectrometry-
based proteomics, we compared the proteomes of pri-
mary motoneurons to motoneuron-like cell lines NSC-34
and N2a, as well as to non-neuronal control cells, at a
depth of 10,000 proteins. We used this resource to eval-
uate the suitability of murine in vitro model systems for
cell biological and biochemical analysis of motoneuron
disease mechanisms. Individual protein and pathway
analysis indicated substantial differences between mo-
toneuron-like cell lines and primary motoneurons, espe-
cially for proteins involved in differentiation, cytoskeleton,
and receptor signaling, whereas commonmetabolic path-
ways were more similar. The proteins associated with
amyotrophic lateral sclerosis also showed distinct differ-
ences between cell lines and primary motoneurons, pro-
viding a molecular basis for understanding fundamental
alterations between cell lines and neurons with respect to
neuronal pathways with relevance for diseasemechanisms.
Our study provides a proteomics resource for motoneuron
research and presents a paradigm of how mass-spectrom-
etry-based proteomics can be used to evaluate disease
model systems. Molecular & Cellular Proteomics 13:
10.1074/mcp.M113.037291, 3410–3420, 2014.
Motoneurons are extremely extended neurons that mediate
the control of all muscle types by the central nervous system.
Therefore, diseases involving progressive motoneuron degen-
eration such as amyotrophic lateral sclerosis (ALS)1 (OMIM:
105400) or spinal muscle atrophy (OMIM: 253300) are partic-
ularly devastating and generally fatal disorders. Today, ALS is
believed to form a phenotypic continuum with the disease
entity frontotemporal lobe degeneration (OMIM: 600274) (1,
2). About 10% of ALS cases are known to be inherited, but the
vast majority are considered sporadic. The number of inher-
ited cases might be underestimated because of incomplete
family histories, non-paternity, early death of family members,
or incomplete penetrance (3).
Mutations in several genes have been reported for the
familial form, including in Sod1 (4), Als2 (5), Setx (6), Vapb (7),
Tardbp (8, 9), Fus/Tls (10, 11), Vcp (12), Pfn1 (13), and several
others (reviewed in Ref. 14). The most frequent genetic cause
of inherited ALS was recently shown to be a hexanucleotide
repeat expansion in an intron of a gene of unknown function
called C9orf72 (15–17). Based on the spectrum of known
mutations, several disease mechanisms for ALS have been
proposed, including dysfunction of protein folding, axonal
transport, RNA splicing, and metabolism (reviewed in Refs.
14, 18, and 19). Despite intensive research, it is still unclear
whether a main common molecular pathway or mechanism
underlies motoneuron degeneration in ALS and frontotempo-
ral lobe degeneration. Spinal muscle atrophy is caused by
homozygous mutations or deletions in the survival of motor
neuron gene (Smn1) that presumably impair the RNA metab-
olism through diminished functionality of the Smn1 gene
product (20). Over recent decades several model systems
have been established to investigate ALS (21). These include
transgenic animal models such as mouse (22), drosophila
(23), and zebrafish (24). In cell-based studies, primary mo-
toneurons cultured from rodent embryos (25) or motoneuron-
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like cell lines are employed. Primary cells are considered to
more closely mimic the in vivo situation, but they are more
challenging to establish and maintain. In contrast, the degree
of functional relevance of cell lines can be difficult to establish,
but they can be propagated without limitation and are well
suited for high-throughput analysis. In particular, the spinal
cord neuron–neuroblastoma hybrid cell line NSC-34 (26) and
the mouse neuroblastoma cell line N2a (27) are widely used
not only to assess motoneuron function, but also to study
disease mechanisms in motoneurons (28, 29).
As proteins are the functional actors in cells, proteomics
should be able to make important contributions to the char-
acterization and evaluation of cellular models. In particular, by
identifying and quantifying the expressed proteins and bioin-
formatically interpreting the results, one can obtain enough
information to infer functional differences. Our laboratory has
previously shown proof of concept of such an approach by
comparing the expression levels of about 4,000 proteins be-
tween primary hepatocytes and a hepatoma cell line (30). Very
recently, mass-spectrometry-based proteomics has achieved
sufficient depth and accuracy to quantify almost the entire
proteome of mammalian cell lines (31–33). Furthermore, new
instrumentation and algorithms now make it possible to per-
form label-free quantification between multiple cellular sys-
tems and with an accuracy previously associated only with
stable isotope labeling techniques (34, 35).
To evaluate the suitability of motoneuron-like cell lines as
cellular model systems for research on ALS and related dis-
orders, we characterized the proteomes of two widely used
cell lines, NSC-34 and N2a, and compared them with the
proteomes of mouse primary motoneurons and non-neuronal
control cell lines. To generate primary motoneurons, we em-
ployed a recently described culturing system that makes it
possible to isolate highly enriched motoneuron populations in
less than 8 h (25). We identified more than 10,000 proteins
and investigated differences in quantitative levels of individual
neuron-associated proteins and pathways related to mo-
toneuron function and disease mechanisms.
EXPERIMENTAL PROCEDURES
Cell Culture—N2a (CCL-131, American Type Culture Collection),
NSC-34 (CED-CLU140, Biozol, Eching, Germany), mouse embryonic
fibroblasts (MEFs) (American Type Culture Collection), and mouse
hepatoma (liver cancer; Hepa1–6) (CRL-1830, American Type Culture
Collection) cell lines were grown in high-glucose Dulbecco’s modified
Eagle’s medium with L-glutamine (PAA/GE, Freiburg, Germany), 10%
FCS (PAA), 1% penicillin/streptomycin (PAA). NSC-34 cells were
directly ordered from the supplier and kept in culture for up to six
passages. All other non-neuronal cell lines are maintained in cryo-
stocks in our laboratory. Cells were harvested with cold PBS. Washed
pellets were flash-frozen in liquid nitrogen for storage.
Primary Motoneurons—CD1 wild-type mice were directly pur-
chased from Charles River (Sulzfeld, Germany). Primary spinal cord
motoneurons from mice were cultured essentially as described pre-
viously (25). Briefly, spinal cords of E12.5 mouse embryos were
dissected and collected in 1.5-ml tubes containing Hank’s Balanced
Salt Solution, Life Technologies GmbH, Darmstadt Germany After
trypsin treatment and trituration, the suspension was enriched for
p75NTR-positive cells via an antibody-panning procedure (25). After
washing and depolarization to remove the cells from the panning dish,
the cells were collected via centrifugation at 400g for 5 min and
resuspended in full medium (Neurobasal (Invitrogen), 1 GlutaMax
(Invitrogen), supplemented with 1 B27 (Invitrogen), 2% horse serum
(Linaris, Dossenheim, Germany)). After counting with a hemocytom-
eter, 7 105 cells were plated on poly-ornithine- (Sigma) and laminin-
coated (Invitrogen) dishes (six-well format, Delta surface, Nunc/
Thermo Fisher Scientific Inc., Waltham, MA) and fed with full medium
supplemented with 5 ng/ml BDNF. 40% of the medium was replaced
after 24 h and every second day after that. In total, cells from 140
CD1 wild-type embryos were used in three experiments. After 7 days
in culture, cells were washed three times with PBS and harvested in
0.5 ml of lysis buffer (4% SDS, 0.1 M DTT, 10 mM Hepes, pH 8.0) per
well.
Sample Preparation for MS Analysis—Cell lysis was performed at
room temperature in lysis buffer (4% SDS, 10 mM Hepes, pH 8.0) with
15 min of sonication (level 5, Bioruptor, Diagenode, Seraing (Ougrée) -
Belgium). Proteins in the lysate were reduced with 10 mM DTT for 30
min and then subjected to 45 min of alkylation with 55 mM iodoacet-
amide. The protein concentration was determined with fluorescence
at 350 nm and compared with a bovine serum albumin standard.
To remove the detergent, we performed acetone precipitation.
Acetone (20 °C) was added to 100 g of proteins to a final concen-
tration of 80% v/v, and proteins were precipitated for at least 2 h at
20 °C. The supernatant was removed after 15 min of centrifugation
(4 °C, 16,000g) followed by washing with 80% acetone (20 °C). The
protein pellet was dissolved in 50 l of 6 M urea/2 M thiourea, 10 mM
Hepes, pH 8.0. After the addition of 1 g of LysC, digestion was
carried out for 3 h at room temperature. We diluted with 4 volumes of
50 mM ammonium bicarbonate and further digested the mixture with
1 g of trypsin overnight at room temperature. The resulting peptide
mixtures were either analyzed directly via a single-shot strategy (36)
or separated into six strong anion exchange fractionations as de-
scribed elsewhere (37). We desalted peptides on C18 StageTips (38).
LC-MS/MS—We separated peptides on a Thermo Scientific EASY-
nLC 1000 HPLC system (Thermo Fisher Scientific, Odense, Den-
mark). Columns (75-m inner diameter, 50-cm length) were in-house
packed with 1.9-m C18 particles (Dr. Maisch GmbH, Ammerbuch-
Entringen, Germany). Peptides were loaded in buffer A (0.5% formic
acid) and separated with a gradient from 7% to 60% buffer B (80%
acetonitrile, 0.5% formic acid) within 3.5 h at 200 nl/min. The column
temperature was set to 40 °C. A quadrupole Orbitrap mass spectrom-
eter (34) (Q Exactive, Thermo Fisher Scientific) was directly coupled to
the liquid chromatograph via a nano-electrospray source. The Q
Exactive was operated in a data-dependent mode. The survey scan
range was set to 300 to 1,650 m/z, with a resolution of 70,000 at m/z
200. Up to the 10 most abundant isotope patterns with a charge of2
were subjected to Higher-energy collisional dissociation (39) with a
normalized collision energy of 25, an isolation window of 2 Th, and a
resolution of 17,500 at m/z 200. To limit repeated sequencing, dy-
namic exclusion of sequenced peptides was set to 30 s. Thresholds
for ion injection time and ion target value were set to 20 ms and 3 
106 for the survey scans and to 60 ms and 106 for the MS/MS scans.
Data were acquired using Xcalibur software (Thermo Scientific).
Data Analysis and Statistics—To process MS raw files, we em-
ployed MaxQuant software (v. 1.3.10.18) (40). We used Andromeda
(41), which is integrated into MaxQuant, to search MS/MS spectra
against the UniProtKB FASTA database (59,345 forward entries; ver-
sion from June 2012). Enzyme specificity was set to trypsin allowing
cleavage N-terminal to proline and up to two miscleavages. Peptides
had to have a minimum length of seven amino acids to be considered
for identification. Carbamidomethylation was set as a fixed modifica-
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tion, and acetylation (N terminus) and methionine oxidation were set
as variable modifications. A false discovery rate (FDR) cutoff of 1%
was applied at the peptide and protein levels. Initial precursor mass
deviation of up to 4.5 ppm and fragment mass deviation up to 20 ppm
were allowed. Precursor ion mass accuracy was improved by time-
dependent recalibration algorithms in MaxQuant. The cutoff score
(delta score) for accepting individual MS/MS spectra was 17.
Nonlinear retention time alignment of all measured samples was
performed in MaxQuant. “Match between runs,” which allows the
transfer of peptide identifications in the absence of sequencing, was
enabled with a maximum retention time window of 1 min. As a library
for “match between runs” in MaxQuant, we employed additional sets
of NSC-34, technical duplicates of E12.5 spinal cord, and technical
duplicates of strong anion exchange fractionated peptides from mo-
toneurons in addition to the biological samples analyzed here (bio-
logical triplicates of NSC-34, N2a, MEF, Hepa 1–6, motoneurons, and
E12.5 spinal cord) (supplemental Table S6). Added individual peptide
intensities are a rough proxy of each protein’s abundance. In order to
ensure improved quantification, we applied further normalization al-
gorithms built into MaxQuant before making quantitative compari-
sons of the cellular systems. Furthermore, we stringently filtered our
data by requiring a minimum peptide ratio count of 2 in MaxLFQ (42).
Protein identification required at least one razor peptide (40). Proteins
that could not be discriminated on the basis of unique peptides were
grouped into protein groups. Furthermore, proteins were filtered for
common contaminants (n  247 (41)) to which laminin sequences
were added to avoid bias resulting from the laminin-coating of plates
in the case of the primary motoneuron culture. Proteins identified only
by site modification were excluded from further analysis. Further-
more, we required a minimum of two valid MaxLFQ quantifications in
at least one group of triplicates. A flowchart describing the individual
steps of the data processing and filtering is presented in supplemen-
tal Table S5.
To quantify fold changes of proteins across samples, we used
MaxLFQ. To visualize these fold changes in the context of individual
protein abundances in the proteome, we projected them onto the
summed peptide intensities normalized by the number of theoretically
observable peptides (43).
Specifically, to compare relative protein abundances between and
within samples, the following transformations to the MaxQuant output
data were performed. First log 2 MaxLFQ differences to the mean log
2 MaxLFQ intensity of each protein group for each sample were
calculated, resulting in intensity-independent log 2 MaxLFQ differ-
ences. Then protein length normalized log 2 protein intensities
(termed iBAQ values in MaxQuant) were added to the MaxLFQ dif-
ferences. The first transformation provides highly accurate informa-
tion about the protein differences between samples, and the second
allows one to compare the abundances of different protein groups.
For statistical and bioinformatic analysis, as well as for visualiza-
tion, we used the open PERSEUS environment, which is part of
MaxQuant. For several calculations and plots we also used the R
framework (44). Pearson correlation was performed on filtered Max-
LFQ intensities omitting missing values (NaN). To identify the most
discriminating proteins in groupwise comparisons, first we performed
imputation of missing values with a normal distribution (width  0.3;
shift  1.8) as described elsewhere (45). Then, we applied the built-in
analysis-of-variance functions in PERSEUS using an FDR of 1% and
S0 of 4 (the S0 parameter sets a threshold for minimum fold change
(46)). For pairwise comparison of proteomes and determination of
significant differences in protein abundances, t test statistics were
applied with a permutation-based FDR of 2% and S0 of 4 (46). The
resulting significant outliers for each of the sample pairs were ana-
lyzed for annotation enrichments.
We used outlier populations derived by means of t test statistics in
order to determine Gene Ontology (GO) (47), KEGG (48), and UniProt
Keyword (49) enrichment of categorical annotations with an intersec-
tion size of at least 8. In Fig. 3 this was done by testing categorical
annotations in individual outlier populations for enrichments com-
pared with the complete dataset via Fisher’s exact test with a
Benjamini–Hochberg corrected FDR of 2% (Fig. 3C). In Fig. 4, no FDR
cutoff was used, but the FDR values are reported (supplemental Table
S3). In cases of identical annotation in both outlier populations, only
the enrichment with highest p value was depicted.
For comparison of the motoneuronal proteome to published tran-
scriptome data (50), we used normalized and filtered log 2 Affymetrix
intensities provided by the authors for transcripts and protein inten-
sities from MaxQuant, which were normalized by protein sequence
length. Transcriptome data were matched in PERSEUS to proteome
data on the basis of gene names, and the median of replicates was
used for comparison.
RESULTS
Deep Proteome Analysis of Motoneuronal Model Sys-
tems—We set out to characterize the proteomes of different
cellular model systems employed in the study of motoneuron
disease mechanisms. Primary motoneurons were isolated
from 12.5-day-old mouse embryos, enriched and differenti-
ated using a recently developed protocol (25), and compared
with two commonly used motoneuron-like cell lines (NSC-34
and N2a) and spinal cord from 12.5-day-old mouse embryos.
As non-neuronal control cells, we employed mouse hepatoma
cells (Hepa 1–6) and MEF cells. To ensure optimal recovery of
membrane proteins such as receptors, which are crucial for
neuronal function, we extracted proteins from cells via lysis in
SDS followed by acetone precipitation. After enzymatic diges-
tion, tryptic peptides were separated by means of reverse
phase liquid chromatography in 4 h gradients and analyzed
on a quadrupole Orbitrap mass spectrometer in single shots
(Fig. 1A). Label-free quantification between biological repli-
cates was highly reproducible, as evidenced by a Pearson
correlation of more than 0.93 (Fig. 1B). Overall we quantified
more than 10,000 proteins and 7,000 to 8,100 proteins in the
individual cellular systems (Fig. 1C, supplemental Tables S1
and S2).
About 75% of all quantified proteins were present in all
analyzed cellular systems (primary cells, motoneuronal cell
lines, and non-neuronal controls). We observed the most pair-
wise overlap of detected proteins between primary neuronal
cells and motoneuronal cell lines (Fig. 1D). However, on a
quantitative level, motoneuronal cell lines correlated more
tightly to the non-neuronal controls than to the primary cells.
This unexpected observation highlights the value of quantita-
tive data (Fig. 1B). Measured protein abundance values
(summed, normalized intensities of the peptides identifying
each protein) covered over 6 orders of magnitude (Fig. 1E). In
all cell systems, some of the most abundant proteins were
histones and ribosomal proteins, in accordance with previous
studies (43, 51, 52). Proteins of housekeeping metabolic pro-
cesses such as spliceosomes or oxidative phosphorylation
were also generally highly abundant. In contrast, neuronal
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proteins involved in receptor signaling or axonal guidance
were relatively low abundant. Because ALS-associated pro-
teins are involved in a variety of cellular processes, they span
almost the entire dynamic range (supplemental Table S2).
For selected gene products—Dctn1, Vcp, Fus, Syp, and
Sox2—we performed Western blot analysis on motoneuron
primary culture, NSC-34, and Hepa 1–6 cell lines. Although
Western blot staining was less easy to interpret than the MS
signals, trends in protein abundance were the same (supple-
mental Figs. S1A–S1C). We also compared our motoneuronal
dataset to a published transcriptome of murine motoneurons
that were differentiated from stem cells with retinoic acid and
sonic hedgehog for 5 days (50) (supplemental Fig. S1E, sup-
plemental Table S4). We observed a moderate and highly
significant correlation (Pearson correlation, 0.49; Pearson p
value, 10e-15) between transcriptome and proteome; how-
ever, many proteins differed strongly between the two data-
sets (supplemental Table S4).
Global Comparison of the Proteomes of Primary Motoneu-
rons, Cell Lines, and Mouse Spinal Cord—After stringent fil-
tering as described in “Experimental Procedures” and sup-
plemental Table S5, we quantitatively compared 7,950
proteins between the model systems on the level of individual
protein expression as well as annotation levels (supplemental
Table S2). The mean standard deviation within biological rep-
licates was less than 2-fold for 95% of the quantified proteins,
demonstrating the quantitative robustness of our measure-
ments (Fig. 2A). Even for the least abundant proteins, the
mean standard deviation was less than 2-fold for more than
99.5% of these proteins (Fig. 2B). As an example, for spinal
cord tissue, the variation between one biological sample
measured twice (technical replicate) was moderately but sig-
FIG. 1. Deep proteome analysis of motoneuronal model systems. A, spinal cord from E12.5 mouse embryo was dissected, and cells were
isolated. P75NTR-positive cells were enriched in an antibody-panning step and grown in culture for 7 days. Motoneuron-like cell lines (N2a,
NSC-34) and control cell lines (MEF, Hepa 1–6) were grown under standard culture conditions. All investigated cellular systems were analyzed
via liquid chromatography coupled to high-resolution mass spectrometry following a single-shot strategy. B, Pearson correlation for MS-
determined protein abundances (MaxLFQ intensities) from single-shot MS measurements. All replicate correlation values were greater than
0.93, and Pearson correlation between different cellular systems was at least 0.7. C, total number of quantified proteins (summed peptide
intensities) in all measurements, including additional replicates of cell lines and spinal cord (“library”) and in individual systems. Between 7,000
and 8,100 proteins were quantified in the individual cellular systems. D, Venn diagram of the distribution of quantified proteins in the
investigated cellular systems, grouped by primary cells, motoneuron-like cell lines, and non-neuronal cell lines. E, ranked MaxLFQ normalized
protein abundances for motoneurons. Indicated are approximated abundance ranges for proteins involved in neuron-specific and general
metabolic processes and in ALS pathology.
FIG. 2. Standard deviation of MaxLFQ quantifications in protein groups within replicates. A, standard deviation of MaxLFQ quantifi-
cations in protein groups for triplicates. B, intensity dependence of MaxLFQ standard deviations for all triplicates. The number of data points
contributing to each bin is depicted above the bins. C, comparison of standard deviations from technical duplicates and biological triplicates
of spinal cord throughout the whole abundance range. Differences between technical and biological replicates are significant (p  0.0001) for
protein intensities of bins 25–30, 30–35, and 35. The number of protein groups for which standard deviations were calculated is depicted
above the bins. Data are plotted as median with 5%–95% percentile.
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nificantly smaller than the variation between biological repli-
cates (Fig. 2C).
We applied principal component analysis (PCA) to evaluate
similarities and dissimilarities on a global scale. Biological
replicates clustered tightly in the PCA space, indicating high
quantitative reproducibility of the experimental setup and the
label-free quantification (Fig. 3A). Motoneurons, spinal cord,
Hepa 1–6, MEFs, and motoneuronal cell lines were clearly
separated in the first two components of PCA. NSC-34 and
N2a together formed a close pair of clusters that was approx-
imately equidistant from the primary cells and the control cell
lines. Although derived from completely different tissues, the
latter are co-located and widely separated from the other
systems. As the difference between them is not profound, we
focused on Hepa 1–6 as a non-neuronal cell line control for
further analysis. Interestingly, the motoneuron primary culture
and the E12.5 spinal cord tissue, although clearly separated,
clustered much closer to each other than to the neuronal and
non-neuronal cell lines.
To assess individual, discriminating proteins in motoneu-
rons, spinal cord, N2a, NSC-34, and Hepa 1–6 cells, we
plotted the “loadings” of the PCA (loadings are the proteins
driving, or responsible for, the separation of the proteomes).
In Fig. 3B, those loadings that also passed a stringent analysis
of variance and fold change (“Experimental Procedures”) are
colored. Within this selection we can distinguish groups of
proteins on the basis of neuronal properties. Proteins that
function in neurite growth, such as Gap43 and Syn2, or in
vesicle release, such as the neuro-secretory protein Vgf, were
shared outliers for both neuron-like cell lines and motoneu-
rons/spinal cord (orange population in Fig. 3B). In contrast,
another group of proteins—such as medium and light chains
of neurofilaments (Nefm and Nefl)—proved to be distinctive
for motoneuronal systems relative to all other systems (green
population in Fig. 3B).
We employed PERSEUS to bioinformatically determine ma-
jor physiological differences among the cellular model sys-
tems via enriched annotations (GO, UniProt Keyword, and
KEGG) (Fig. 3C, supplemental Fig. S3, supplemental Table
S3). E12.5 spinal cord consists of a mixed population of
undifferentiated cells. Consistent with this, annotation enrich-
Fig. 3. Global proteomic comparison of motoneuron-like cell
lines, embryonic spinal cord, unrelated cell lines, and primary
motoneurons. A, PCA of protein expression values of the different
systems. Component 1 and component 2 account for 54.8% of the
data variation. B, significant outliers from analysis of variance (FDR
cutoff 1%, S0 fold-change cutoff 4) are depicted in red in the PCA
loading distribution (gray dots). Proteins driving the separation are
colored according to the PCA plot in A. C, analyses of enriched
annotation (Fisher’s exact test) for t test significant (FDR cutoff 2%,
S0 fold-change cutoff  4) outlier populations. The six most enriched
(log 2) annotations from UniProt Keywords (Key), GO biological pro-
cess (GOBP), GO cellular compartment (GOCC), and KEGG are
depicted.
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ments for primary motoneurons demonstrated a stronger neu-
ronal character relative to spinal cord (supplemental Fig. S3).
NSC-34 and N2a cells differed even more from primary mo-
toneurons with respect to neuron-specific proteins. For in-
stance, neuron-associated annotations such as GO biological
process “neurotransmitter transport” were enriched more
than four times in motoneurons relative to NSC-34 and N2a
(Fig. 3C). Functions that were enriched for these neuronal cell
lines were mainly related to DNA metabolism, presumably as
a consequence of the fact that they are proliferating whereas
the primary motoneurons are terminally differentiated.
Although they are derived from neuroblastoma, the overall
neuronal characteristics of NSC-34 and N2a are not profound.
Nevertheless, comparison of NSC-34 and N2a cells to non-
neuronal cell lines revealed some patterns that are character-
istic for neurons—for instance, enrichment of proteins in-
volved in neuron projection and the neuronal cytoskeleton.
These observations based on proteomic quantification high-
light fundamental differences between neuronal cell lines and
primary motoneurons with respect to their protein repertoire
for neuronal differentiation and function.
To characterize differences in protein patterns among pri-
mary motoneurons, motoneuronal cell lines, and non-neuro-
nal cell lines in more detail, we computed enrichment values
and p values for annotation categories for binary comparisons
of the cellular systems (Fig. 4, supplemental Table S3). Com-
parison of primary motoneurons to NSC-34 and N2a cells
revealed striking differences for neuronal categories, with a
large overrepresentation in the motoneurons.
Evaluation of Axon Growth, Guidance, and Polarity—Im-
paired establishment and maintenance of neuronal morphol-
ogy is a central pathological aspect in neurodegenerative
disorders (53). We had observed the corresponding annota-
tions such as neuron projection (GO cellular component) and
axon guidance (KEGG) to be de-enriched in the motoneuronal
cell lines, and we next wished to extract the expression level
of key factors in these processes (Fig. 5A). Illustrating the use
of the dataset as a resource, we observed that proteins im-
portant for axonal outgrowth like Slits/Robos, Semaphorins,
Netrins, or Ephrins or proteins involved in morphological
maintenance such as Mapt were either missing or underrep-
resented in NSC-34 and N2a.
Evaluation of Excitability and Synaptic Function—Neu-
rotransmitter-receptor signaling and excitability are main fea-
tures of neuronal cell types that differ according to cellular
functionality. We assessed the abundance of proteins in-
volved in receptor signaling (KEGG “neuroactive receptor-
ligand interaction,” voltage-gated channel (UniProt Keyword),
and ligand-gated ion channel (UniProt Keyword); Fig. 5). Strik-
ingly, many receptors were underrepresented or even not
detected in the NSC-34 and N2a cells. In particular, glutamate
receptors were present almost exclusively in isolated mo-
toneurons, and to a lesser extent in spinal cord, but not in the
neuronal cell lines. The serotonin receptor functions in fast
depolarization of neurons and is not expected to be present in
motoneurons. Accordingly, we did not detect it in motoneu-
rons. It was, however, identified in NSC-34 and N2a cells,
suggesting that they do not faithfully represent motoneuronal
characteristics in this respect. Overall, slightly more receptor
proteins were present in N2a than in NSC-34 cells. Despite
the striking differences of both neuronal cell lines relative to
primary motoneurons, their protein abundance patterns
FIG. 4. Evaluation of neuronal pathway enrichments and neu-
ron-specific protein abundances. A–C, pairwise comparison of en-
riched annotations in different cellular model systems. Annotations
are depicted by their enrichment factor and statistical significance,
similar to volcano plots for protein populations.
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clearly indicated a neuronal inheritance compared with Hepa
1–6.
Evaluation of ALS-associated Proteins—As mentioned
above, ALS-associated proteins span a wide range of cellular
functions and are not generally neuron specific. The presence
and abundance of these ALS-associated proteins are impor-
tant aspects for studying disease mechanisms and therefore
for evaluating the suitability of disease models. We found that
most ALS-associated proteins were indeed present in the
proteomes of NSC-34 and N2a cell lines (Fig. 6). Compared
with neuronal proteins, the differences between the cellular
systems were smaller but still distinct. For example, whereas
we observed major expression-level differences for ALS-as-
sociated neuron-specific proteins such as the Eph4 receptor,
the neurofilament protein Nefl, and the microtubule-associ-
ated Mapt, levels were similar for proteins that are not neuron
specific, such as Sod1.
DISCUSSION
Motoneuron diseases such as ALS or spinal muscle atrophy
are incurable, and no effective symptomatic treatments are
available. Researchers make use of a variety of different cell
culture model systems to unravel disease pathways and to
understand pathological mechanisms (19, 21, 54). However,
the proteomics properties of these systems have never been
assessed on a global level. Here we provide a large-scale and
quantitative analysis comparing the proteomes of primary
motoneurons to the neuroblastoma cell lines NSC-34 and
N2a, as well as to unrelated cell lines. The quantitative inven-
tory of expressed proteins in these systems should serve as a
valuable resource for the community. We have made these
data easily accessible in the MaxQB database (55). Users can
query the expression rank order of proteins of interest, se-
quence coverage, high-resolution MS/MS spectra of pep-
tides, and many other features of the proteome. Moreover,
our study presents a generic approach with which to evaluate
model systems using high-resolution quantitative mass-spec-
trometry-based proteomics.
Unexpectedly, our proteomics results at both global and
individual protein levels only place the neuronal cell line mod-
els halfway between the actual target tissue (in vivo motoneu-
rons) and completely unrelated cell lines derived from mouse
liver cancer or mouse embryos. We found proteins with high
relevance for neuronal function, in particular neurotransmitter
receptors and proteins involved in neuronal excitability and
neurotransmitter release, to be strongly underrepresented in
NSC-34 and N2a. The abundances of glutamate receptors
were considerably lower as well, suggesting nonexistent or at
least significantly diminished neuronal excitability. Because
disease pathways associated with excitotoxicity, in particular
glutamate toxicity, are frequent areas of focus in ALS research
(19, 56), this leads us to question the suitability of these cell
lines for such studies. The nerve growth factor receptor is
highly abundant during development and when neurons are
lesioned or degenerating (57–60). In accordance with this,
we found nerve growth factor receptor to be highly abun-
dant in E12.5 spinal cord, whereas it was down-regulated in
primary motoneurons, which are terminally differentiated.
This receptor also showed relatively high abundance in
NSC-34 and N2a cell lines, further suggesting differences
relative to motoneurons.
Mechanisms that destabilize axons are a major focus of
research in neurodegeneration (53). In this regard it is impor-
FIG. 5. Evaluation of neuron-specific protein abundances. A, B,
abundances of selected proteins that are members of the neuronal
annotation classes in Fig. 3. The normalized MS-derived abundance
values allow comparisons within and between cellular systems.
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tant to take the observed differences for cytoskeleton-asso-
ciated proteins—for instance, for Mapt and Nefl, which were
much lower in N2a and NSC-34 cells than in primary mo-
toneurons—into account. In addition, various members of the
axon guidance family such as Slits/Robos, Semaphorins, Ne-
trins, or Ephrins showed altered abundance patterns in
NSC-34 and N2a. Together, these observations raise the
question of whether N2a and NSC-34 cells are reliable models
regarding motoneuronal structure, in particular axon growth
and maintenance. Although both cell lines certainly exhibit
aspects of neuronal morphology, at the proteomics level,
neuronal features mainly become apparent in comparison to
unrelated, non-neuronal cell lines. Our data thus indicate that
the morphological tendency toward motoneurons does not
correspond directly to the protein level. This also suggests
that morphological comparisons can usefully be comple-
mented by quantitative proteomic data.
In contrast to these motoneuron-specific pathways, univer-
sal metabolic and housekeeping pathways were less altered
between cell lines and primary cells. The main difference
highlighted by bioinformatic analysis of the proteomic data
was an up-regulation of DNA metabolism (Fig. 3). This is
because cell culture favors rapidly dividing cells, and any
non-essential metabolic pathways are counter-selected. The
same reasoning might also explain the down-regulation of
pathways such as receptor signaling and of proteins impor-
tant for the maintenance of complex cellular morphologies
noted above.
We further found differences in the expression levels of
some, but not all, ALS-associated proteins in the analyzed
cellular systems. For many of them, such as mutant Sod1 or
wild-type Tdp-43 (61), even relatively small expression levels
(2-fold overexpression relative to wild-type levels, for instance
(62)) are known to have severe effects on the pathogenic
cascade and the onset of symptoms (63). Furthermore, mo-
toneuron diseases are highly cell-type specific, suggesting a
narrow physiological niche for manifestation of a pathological
phenotype. Therefore, in addition to the fact that moderate
differences in ALS protein abundances may be very impor-
tant, the general motoneuronal characteristics as evidenced
by quantitative proteomics need to be taken into account.
Thus neuroblastoma cell lines are limited in terms of their
suitability to serve as model systems for motoneurons for the
study of ALS-relevant functional mechanisms, as they neither
reconstitute global motoneuronal properties nor faithfully
mimic motoneurons on the individual protein level. However,
they still retain neuronal character in comparison to other cell
lines, rendering them a valid choice for some biological inves-
tigations and high-throughput screens.
In conclusion, we here present a resource for motoneuron
disease research. Because of the high protein coverage in
cell lines and primary motoneurons, our data highlight im-
portant cellular pathways unique to or enriched in neurons
and functionally relevant in motoneurons. Our study exem-
plifies how quantitative proteomics can be used to critically
evaluate the suitability of model systems in general. De-
FIG. 6. Evaluation of ALS-associated protein abundances. A, ranked abundances of ALS-associated proteins in the context of the entire
proteome. B, normalized MS-derived expression values of the same proteins as in A, depicted as a heat map for motoneurons, NSC-34, N2a,
Hepa 1–6, and E12.5 spinal cord.
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pending on the intended experiments, the best cellular
model system can be chosen according to the presence or
abundance of the involved receptors or neuronal pathways
(such as ALS or signaling studies). In the current context, for
instance, it would be interesting to compare the proteome
of primary motoneurons to in vitro differentiated motoneu-
rons derived from induced patient-derived pluripotent stem
cells with a view to evaluate these exciting and promising
new model systems.
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